Structure Therapeutics’ experimental pill aleniglipron just delivered strong Phase 2b weight-loss data. Here’s why its small-molecule design matters and how it stacks up against the GLP-1 pills already on shelves.
A year after Wegovy became the first GLP-1 approved for MASH, new AASLD clinical guidance and real prescribing data show what the ESSENCE trial results actually mean for the millions of Americans with fatty liver disease.
Oral semaglutide, Foundayo, and a pipeline of small-molecule challengers are all fighting for the same needle-averse patient. Here’s how every oral GLP-1 option compares, dosing rules and all.
BPC-157 just cleared a real hurdle — a favorable PCAC committee vote toward FDA’s 503A Bulk Drugs List — but it’s still not formally authorized for compounding. Here’s the full regulatory timeline and what’s still ahead.
The FDA’s proposal to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list just finished its comment period. Here’s what changes, what doesn’t, and why the shortage-era compounding market is ending.
Every GLP-1 headline throws around a weight-loss percentage. Here’s how to actually read the trial behind it — phases, placebo adjustment, endpoints, and the tricks press releases use to make numbers look bigger than they are.
New to research peptides in 2026? Start here — a practical orientation covering what research peptides actually are, the current legal landscape, how to evaluate vendors, and where to go next.
Fifty-four thousand customers. Eighty countries. Five million dollars in proceeds. And a product that, when federal investigators finally tested it,
Every peptide research forum has the same recurring thread: someone did the reconstitution math by hand, dropped a decimal, and
Somewhere between December 2024 and March 2025, officers at U.S. Customs and Border Protection’s Cincinnati port of entry started noticing
